Profile data is unavailable for this security.
About the company
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
- Revenue in USD (TTM)56.42m
- Net income in USD-176.98m
- Incorporated2009
- Employees284.00
- LocationNurix Therapeutics Inc1700 Owens St Ste 205SAN FRANCISCO 94158-0006United StatesUSA
- Phone+1 (415) 660-5320
- Fax+1 (415) 525-4200
- Websitehttps://www.nurixtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | 43.09m | -522.28m | 1.40bn | 526.00 | -- | 1.46 | -- | 32.53 | -5.45 | -5.45 | 0.4509 | 9.46 | 0.0357 | -- | 5.62 | 81,912.55 | -43.22 | -31.34 | -47.07 | -34.53 | -- | -- | -1,212.19 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Cassava Sciences Inc | 0.00 | -17.66m | 1.54bn | 29.00 | -- | 9.26 | -- | -- | -0.3772 | -0.3772 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -8.91 | -30.74 | -10.98 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Neumora Therapeutics Inc | 0.00 | -293.70m | 1.55bn | 108.00 | -- | 4.85 | -- | -- | -1.77 | -1.77 | 0.00 | 2.00 | 0.00 | -- | -- | 0.00 | -65.46 | -- | -70.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| BioCryst Pharmaceuticals Inc | 412.58m | -123.82m | 1.55bn | 536.00 | -- | -- | -- | 3.76 | -0.6073 | -0.6073 | 2.01 | -2.26 | 0.8136 | 0.4297 | 6.54 | 769,736.90 | -24.42 | -47.95 | -32.17 | -64.89 | 98.06 | 97.06 | -30.01 | -114.94 | 2.73 | -0.488 | 2.29 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| Viridian Therapeutics Inc | 302.00k | -257.08m | 1.55bn | 96.00 | -- | 3.00 | -- | 5,146.21 | -4.31 | -4.31 | 0.005 | 8.94 | 0.0006 | -- | 5.21 | 3,212.77 | -46.71 | -55.59 | -49.63 | -60.32 | -- | -- | -85,127.15 | -5,678.12 | -- | -- | 0.0282 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
| Travere Therapeutics Inc | 203.45m | -348.96m | 1.57bn | 380.00 | -- | -- | -- | 7.69 | -4.52 | -4.56 | 2.63 | -0.3909 | 0.3043 | 0.7192 | 10.24 | 535,386.80 | -52.19 | -36.95 | -69.25 | -44.77 | 95.21 | 95.92 | -171.52 | -165.79 | 1.68 | -- | 1.09 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Nurix Therapeutics Inc | 56.42m | -176.98m | 1.58bn | 284.00 | -- | 3.98 | -- | 28.08 | -2.91 | -2.91 | 0.9222 | 5.62 | 0.1373 | -- | -- | 198,676.10 | -43.07 | -33.01 | -52.51 | -39.66 | -- | -- | -313.65 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| Dynavax Technologies Corp | 260.81m | 20.48m | 1.62bn | 408.00 | 101.25 | 2.38 | 64.90 | 6.23 | 0.1221 | 0.1221 | 1.83 | 5.19 | 0.2563 | 0.80 | 4.36 | 639,242.60 | 2.01 | 4.16 | 2.14 | 5.71 | 82.85 | 64.83 | 7.85 | 9.19 | 12.34 | -- | 0.247 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Recursion Pharmaceuticals Inc | 65.18m | -377.75m | 1.65bn | 500.00 | -- | 3.13 | -- | 25.29 | -1.53 | -1.53 | 0.2631 | 1.83 | 0.096 | -- | 24.06 | 130,368.00 | -55.66 | -- | -65.45 | -- | 35.07 | -- | -579.51 | -- | -- | -- | 0.0519 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| Xencor Inc | 85.16m | -198.24m | 1.69bn | 280.00 | -- | 2.33 | -- | 19.80 | -3.20 | -3.20 | 1.37 | 10.35 | 0.0967 | -- | 2.61 | 304,157.20 | -22.89 | -3.70 | -24.90 | -4.12 | -- | -- | -236.81 | -15.92 | -- | -- | 0.0243 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -110.55m | 1.72bn | 148.00 | -- | 1.92 | -- | -- | -2.21 | -2.21 | 0.00 | 15.66 | 0.00 | -- | -- | 0.00 | -19.23 | -- | -20.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Arvinas Inc | 161.10m | -308.60m | 1.73bn | 445.00 | -- | 2.94 | -- | 10.71 | -4.79 | -4.79 | 2.38 | 8.53 | 0.1448 | -- | 14.01 | 362,022.50 | -27.73 | -22.01 | -37.81 | -26.47 | -- | -- | -191.56 | -316.55 | -- | -- | 0.001 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Celldex Therapeutics, Inc. | 9.98m | -154.08m | 1.74bn | 160.00 | -- | 2.21 | -- | 174.37 | -2.57 | -2.57 | 0.164 | 11.85 | 0.0181 | -- | 18.07 | 62,350.00 | -27.93 | -29.65 | -29.53 | -31.42 | -- | -- | -1,544.48 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| Fortrea Holdings Inc | 2.77bn | -233.60m | 1.75bn | 15.50k | -- | 1.16 | -- | 0.6297 | -2.62 | -3.40 | 31.09 | 16.87 | 0.6954 | -- | 3.20 | 154,155.60 | -5.85 | -- | -7.29 | -- | 18.49 | -- | -8.42 | -- | -- | -0.6141 | 0.4263 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Nurix Therapeutics Inc's reporting currency: US Dollar USD
48.54%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 5.16m | 7.29% |
| Redmile Group LLCas of 30 Sep 2024 | 4.28m | 6.04% |
| Baker Bros. Advisors LPas of 30 Sep 2024 | 3.88m | 5.48% |
| Deep Track Capital LPas of 30 Sep 2024 | 3.87m | 5.46% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 3.86m | 5.45% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 3.22m | 4.55% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 2.97m | 4.19% |
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2024 | 2.55m | 3.60% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.37m | 3.35% |
| ARK Investment Management LLCas of 30 Sep 2024 | 2.22m | 3.13% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
